Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
8.50
+0.05 (0.59%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 16.5, with a low estimate of 11 and a high estimate of 22. The average target predicts an increase of 94.12% from the current stock price of 8.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OCUL stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +76.47% | Dec 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +76.47% | Nov 15, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $22 | Buy | Initiates | $22 | +158.82% | Oct 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +64.71% | Oct 16, 2024 |
| Baird | Baird | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +100.00% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
65.11M
from 58.44M
Increased by 11.40%
Revenue Next Year
73.95M
from 65.11M
Increased by 13.58%
EPS This Year
-1.20
from -1.02
EPS Next Year
-1.09
from -1.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 69.4M | 90.4M | 136.2M | |||
| Avg | 65.1M | 74.0M | 86.8M | |||
| Low | 61.1M | 63.9M | 67.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 18.8% | 38.9% | 84.2% | |||
| Avg | 11.4% | 13.6% | 17.3% | |||
| Low | 4.5% | -1.9% | -8.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.99 | -0.99 | -0.47 | |||
| Avg | -1.20 | -1.09 | -1.08 | |||
| Low | -1.23 | -1.23 | -1.30 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.